Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 352 of the 356 references it cites were found in a registry or an index; none of the 390 sources its claims cite is checked for support yet.
Abstract
OBJECTIVE: The aim was to formulate practice guidelines for the diagnosis and treatment of polycystic ovary syndrome (PCOS). PARTICIPANTS: An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer developed the guideline. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize supporting evidence. CONCLUSIONS: We suggest using the Rotterdam criteria for diagnosing PCOS (presence of two of the following criteria: androgen excess, ovulatory dysfunction, or polycystic ovaries). Establishing a diagnosis of PCOS is problematic in adolescents and menopausal women. Hyperandrogenism is central to the presentation in adolescents, whereas there is no consistent phenotype in postmenopausal women. Evaluation of women with PCOS should exclude alternate androgen-excess disorders and risk factors for endometrial cancer, mood disorders, obstructive sleep apnea, diabetes, and cardiovascular disease. Hormonal contraceptives are the first-line management for menstrual abnormalities and hirsutism/acne in PCOS. Clomiphene is currently the first-line therapy for infertility; metformin is beneficial for metabolic/glycemic abnormalities and for improving menstrual irregularities, but it has limited or no benefit in treating hirsutism, acne, or infertility. Hormonal contraceptives and metformin are the treatment options in adolescents with PCOS. The role of weight loss in improving PCOS status per se is uncertain, but lifestyle intervention is beneficial in overweight/obese patients for other health benefits. Thiazolidinediones have an unfavorable risk-benefit ratio overall, and statins require further study.
Overview
CoChat Summary
TL;DR
This Endocrine Society clinical practice guideline recommends using the Rotterdam criteria to diagnose PCOS in adults and emphasizes excluding mimics and assessing associated metabolic, cardiovascular, endometrial, mood, and sleep morbidity. It recommends hormonal contraceptives as first-line management for menstrual abnormalities and hirsutism/acne, clomiphene (or comparable estrogen modulators) as first-line therapy for anovulatory infertility, and metformin for T2DM/IGT or as second-line therapy for menstrual irregularity when hormonal contraceptives cannot be used.
Key findings
- PCOS diagnosis in adults should be made if two of three Rotterdam criteria are met—androgen excess, ovulatory dysfunction, or polycystic ovaries—after excluding thyroid disease, hyperprolactinemia, and nonclassic congenital adrenal hyperplasia; in adolescents, diagnosis should require clinical and/or biochemical hyperandrogenism plus persistent oligomenorrhea, because anovulatory symptoms and PCO morphology are not sufficient.
- Women with PCOS are at increased risk for impaired glucose tolerance and type 2 diabetes: the guideline states a 5- to 10-fold increased risk of developing T2DM, with overall glucose intolerance prevalence of 30–35% and T2DM in 3–10%; nonobese women with PCOS had 10–15% IGT and 1–2% T2DM.
- Hirsutism is present in approximately 65–75% of patients with PCOS, and PCOS represents the major cause of hirsutism; in a large study of patients with clinical hyperandrogenism, 72.1% of 950 patients were diagnosed with PCOS.
- Endometrial cancer risk is increased: a 31-year UK follow-up showed a 3.5 increased relative risk, and a meta-analysis reported RR = 2.7 (95% CI, 1.0–7.29), confirmed by a subsequent systematic review with a 3-fold increased risk.
- Depression and sleep-disordered breathing are also increased: one study reported major depression episode/recurrent depression OR 3.8 (95% CI, 1.5–8.7; P = .001) and suicide attempts seven times higher in PCOS cases vs controls; women with PCOS were 30 times more likely to have sleep-disordered breathing and nine times more likely to have daytime sleepiness after controlling for BMI.
Methods
- An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer developed the guideline using the GRADE system to describe recommendation strength and evidence quality.
- Consensus was reached through one group meeting, several conference calls, and e-mail communications; committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts.
- Two systematic reviews were conducted to summarize supporting evidence; recommendations use “we recommend” with number 1 for strong recommendations and “we suggest” with number 2 for weak recommendations, with cross-filled circles indicating evidence quality.
Limitations
- The guideline states that there are no adequately powered, randomized, double-blind, placebo-controlled trials in adolescents with PCOS; no large randomized trials of exercise in PCOS; and no long-term data assessing the effect of hormonal contraceptives on glucose tolerance in nondiabetic and diabetic women with PCOS.
- It states that there are currently no diagnostic criteria for PCOS in perimenopausal and menopausal women, no age-related testosterone cutoffs, and that testosterone assays used to diagnose hyperandrogenemia in women are imprecise.
- It notes that the Rotterdam ultrasound PCO criteria were not validated for adolescents, that there is a lack of well-defined cutoff points for androgen levels during normal pubertal maturation, and that many recommendations are weak because evidence is limited or inconclusive.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 201 Not checked · 50 Own results and interpretations
In the paper
“However, hirsutism was a major symptom in about 60% of adolescents in one study (27) and may be suggestive of PCOS in adolescents (28).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 1.0 Diagnosis of PCOS
What the sources say
- Not checked yetcites [27] Pfeifer SM, Kives S Polycystic ovary syndrome in the adolescent. Obstet Gynecol Clin North Am. 2009; 36: 129– 152. 19344852
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“but our systematic review did not confirm this (211).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [211] Domecq JP, Prutsky G, Mullan R, et al Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013–2385. 24092832
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“although there were significant improvements in some metabolic parameters (mainly glycemic effects related to improvements in fasting blood glucose and insulin levels) (249, 250).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [249] Tang T, Glanville J, Orsi N, Barth JH, Balen AH The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006; 21: 1416– 1425. 16501038
- Not checked yetcites [250] Domecq JP, Prutsky G, Mullan R, et al Adverse effects of common treatments for polycystic ovary syndrome: a systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013-2374. PMC5399491 24092830
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found little evidence to support lifestyle change as an infertility treatment”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Our own meta-analysis showed that weight loss had minimal effects on hirsutism and fertility”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [249] Tang T, Glanville J, Orsi N, Barth JH, Balen AH The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006; 21: 1416– 1425. 16501038
- Not checked yetcites [250] Domecq JP, Prutsky G, Mullan R, et al Adverse effects of common treatments for polycystic ovary syndrome: a systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013-2374. PMC5399491 24092830
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
146 more claims
Create a free account to see all 252 claims and to verify the 390 references still open.
- It may state two separate claims as one. 78
- Probably not a substantial claim. 34
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Based on current guidelines, metformin is indicated in PCOS in some scenarios to improve fertility (Teede et al. , 2011; Legro et al. , 2013), for management of menstrual irregularity if women are unable to take OCPs, and in co-existent prediabetes or DM2, where lifestyle modification fails (Legro et al. , 2013).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Legro et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the interim there is inadequate evidence on the impact of metformin on glucose tolerance in prediabetes and DM2 specifically in PCOS, but based on data in general populations, current guidelines recommend using metformin in obese women with PCOS who have prediabetes or DM2 (Legro et al. , 2013).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Legro et al. , 2013
Experimental — accuracy not yet measuredIn the citing paper
“It is indicated in combination with COCs, especially for overweight or obese patients, or when COCs are contraindicated [46].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [46]
Citations
Cites
1 retracted
Shaw, L. J., Bairey Merz, C. N., Azziz, R., Stanczyk, F. Z., Sopko, G., Braunstein, G. D., Kelsey, S. F., Kip, K. E., Cooper-DeHoff, R. M., Johnson, B. D., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0425 · Cited by 427
RetractedReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“implementation of evidence-based guidelines (4).”
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
The Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Self-citationThe diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718 · cited 1×
“Cushing’s syndrome Many of the signs and symptoms of PCOS can overlap with Cushing’s (ie, striae, obesity, dorsocervical fat (ie, buffalo hump, glucose intolerance); however, Cushing’s is more likely to be present when a large number of signs and symptoms, especially those with high discriminatory index (eg, myopathy,…”
BackgroundThe Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population
Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yildiz, B. O. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032046 · Cited by 2,712 · cited 1×
“Overall, hirsutism is present in approximately 65–75% of patients with PCOS (although lower in Asian populations) (15, 52).”
BackgroundPhysical Fitness and All-Cause Mortality: A Prospective Study of Healthy Men and Women
Blair, S. N. (1989) · JAMA · doi:10.1001/jama.1989.03430170057028 · Cited by 2,658 · cited 1×
“diovascular fitness, as measured by maximal oxygen consumption during exercise, is an independent predictor of cardiovascular mortality (229).”
BackgroundAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143 · cited 1×
“Similarly, androgen levels decline with age in women with and without PCOS (serum T declines 50% between the ages of 20 and 40 y) (43–45), with reports of improved menstrual frequency in PCOS (46, 47), although there is little evidence to support a decline in serum T associated with the menopause transition per se (43…”
BackgroundSelf-citation
Research works printed but not linked: 1
- [286]Tanner JM Growth and endocrinology of the adolescent. In: Gardner LI, ed. Endocrine and Genetic Diseases of Childhood and Adolescents. 2nd ed Philadelphia, PA: WB Saunders: 1975: 14.
Cited by
The Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Self-citationPolycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment
Escobar-Morreale, H. F. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.24 · Cited by 2,083
Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.57 · Cited by 2,005
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., & the International PCOS Network (2018) · Clinical Endocrinology · doi:10.1111/cen.13795 · Cited by 1,823
Guidelines of care for the management of acne vulgaris
Zaenglein, A. L., Pathy, A. L., Schlosser, B. J., Alikhan, A., Baldwin, H. E., Berson, D. S., Bowe, W. P., Graber, E. M., Harper, J. C., Kang, S., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.12.037 · Cited by 1,597
“The differential diagnosis of PCOS includes thyroid disease, prolactin excess, and nonclassical congenital adrenal hyperplasia, among others.(168) Hormonal testing and interpretation of testing is complex.”
BackgroundTeede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., International PCOS Network, Andersen, M., et al. (2018) · Human Reproduction · doi:10.1093/humrep/dey256 · Cited by 1,593
Self-citationHampl, S. E., Hassink, S. G., Skinner, A. C., Armstrong, S. C., Barlow, S. E., Bolling, C. F., Avila Edwards, K. C., Eneli, I., Hamre, R., Joseph, M. M., et al. (2023) · Pediatrics · doi:10.1542/peds.2022-060640 · Cited by 1,389
Criteria, Prevalence, and Phenotypes of Polycystic Ovary Syndrome
Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavrilova-Jordan, L., & Azziz, R. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.05.003 · Cited by 1,358
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., Andersen, M., Azziz, R., et al. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.05.004 · Cited by 1,325
“Current guidelines either are limited in breadth, do not follow rigorous best practice in development, have not involved consumers, or are outdated (6-10), resulting in inconsistent guidance for clinicians and women alike.”
BackgroundSelf-citationDiagnosis and Management of Infertility: A Review
Carson, S. A., & Kallen, A. N. (2021) · JAMA · doi:10.1001/jama.2021.4788 · Cited by 1,294
Styne, D. M., Arslanian, S. A., Connor, E. L., Farooqi, I. S., Murad, M. H., Silverstein, J. H., & Yanovski, J. A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2573 · Cited by 1,282
“Given variability in testosterone levels and the poor standardization of assays, it is difficult to define an absolute level that is diagnostic of PCOS or other causes of hyperandrogenism (familiarity with local assays recommended) (63).”
Self-citationKumar, S., & Kelly, A. S. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.09.017 · Cited by 1,277
Fassnacht, M., Dekkers, O. M., Else, T., Baudin, E., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assie, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 961
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
Balen, A. H., Morley, L. C., Misso, M., Franks, S., Legro, R. S., Wijeyaratne, C. N., Stener-Victorin, E., Fauser, B. C. J. M., Norman, R. J., & Teede, H. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw025 · Cited by 705
Self-citationDimitriadis, E., Menkhorst, E., Saito, S., Kutteh, W. H., & Brosens, J. J. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00228-z · Cited by 702
Pregnancy complications in women with polycystic ovary syndrome
Palomba, S., de Wilde, M. A., Falbo, A., Koster, M. P. H., La Sala, G. B., & Fauser, B. C. J. M. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv029 · Cited by 691
“Of note, women with PCOS, especiallywhenobese, have an increased incidenceof symptoms of sleep-disordered breathing (Legro et al., 2013; Shreeve et al., 2013) that are independent risk factors for pregnancy complications (Bisson et al.”
BackgroundThe polycystic ovary syndrome: a position statement from the European Society of Endocrinology
Conway, G., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Franks, S., Gambineri, A., Kelestimur, F., Macut, D., Micic, D., Pasquali, R., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0253 · Cited by 676
Self-citationDe Souza, M. J., Nattiv, A., Joy, E., Misra, M., Williams, N. I., Mallinson, R. J., Gibbs, J. C., Olmsted, M., Goolsby, M., Matheson, G., et al. (2014) · British Journal of Sports Medicine · doi:10.1136/bjsports-2013-093218 · Cited by 661
“77 79 The primary care physician should refer to or consult with an endocrinologist for endocrine disorders they are not experienced in diagnosing or treating.”
BackgroundWitchel, S. F., Oberfield, S. E., & Peña, A. S. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00078 · Cited by 653
Overweight and Obesity in Children and Adolescents
Koyuncuoğlu Güngör, N. (2014) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.1471 · Cited by 624
Goodman, N. F., Cobin, R. H., Futterweit, W., Glueck, J. S., Legro, R. S., & Carmina, E. (2015) · Endocrine Practice · doi:10.4158/ep15748.dsc · Cited by 623
Self-citationFunctional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline
Gordon, C. M., Ackerman, K. E., Berga, S. L., Kaplan, J. R., Mastorakos, G., Misra, M., Murad, M. H., Santoro, N. F., & Warren, M. P. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00131 · Cited by 600
Self-citationMcCartney, C. R., & Marshall, J. C. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1514916 · Cited by 581
The crucial role and mechanism of insulin resistance in metabolic disease
Zhao, X., An, X., Yang, C., Sun, W., Ji, H., & Lian, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1149239 · Cited by 557
Martin, K. A., Chang, R. J., Ehrmann, D. A., Ibanez, L., Lobo, R. A., Rosenfield, R. L., Shapiro, J., Montori, V. M., & Swiglo, B. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2437 · Cited by 512
Self-citationTransfer of Fresh versus Frozen Embryos in Ovulatory Women
Shi, Y., Sun, Y., Hao, C., Zhang, H., Wei, D., Zhang, Y., Zhu, Y., Deng, X., Qi, X., Li, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705334 · Cited by 511
Self-citationSingle-cell roadmap of human gonadal development
Garcia-Alonso, L., Lorenzi, V., Mazzeo, C. I., Alves-Lopes, J. P., Roberts, K., Sancho-Serra, C., Engelbert, J., Marečková, M., Gruhn, W. H., Botting, R. A., et al. (2022) · Nature · doi:10.1038/s41586-022-04918-4 · Cited by 465
Ibáñez, L., Oberfield, S. E., Witchel, S., Auchus, R. J., Chang, R. J., Codner, E., Dabadghao, P., Darendeliler, F., Elbarbary, N. S., Gambineri, A., et al. (2017) · Hormone Research in Paediatrics · doi:10.1159/000479371 · Cited by 463
Self-citationDay, F. R., Hinds, D. A., Tung, J. Y., Stolk, L., Styrkarsdottir, U., Saxena, R., Bjonnes, A., Broer, L., Dunger, D. B., Halldorsson, B. V., et al. (2015) · Nature Communications · doi:10.1038/ncomms9464 · Cited by 459
Self-citationGibson-Helm, M., Teede, H., Dunaif, A., & Dokras, A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2963 · Cited by 428
“PCOS is exacerbated by obesity (11), and lifestyle management (weight management or loss, healthy diet and exercise) and the oral contraceptive pill are first-line treatments (12, 13).”
BackgroundPolycystic ovarian syndrome (PCOS): Long-term metabolic consequences
Anagnostis, P., Tarlatzis, B. C., & Kauffman, R. P. (2018) · Metabolism · doi:10.1016/j.metabol.2017.09.016 · Cited by 416
The Potential Implications of a PCOS Diagnosis on a Woman's Long-Term Health Using Data Linkage
Hart, R., & Doherty, D. A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3886 · Cited by 391
“tional Health and Medical Research Council (3), and in the United States by The Endocrine Society statement (4).”
BackgroundEndometrial function in women with polycystic ovary syndrome: a comprehensive review
Palomba, S., Piltonen, T. T., & Giudice, L. C. (2021) · Human Reproduction Update · doi:10.1093/humupd/dmaa051 · Cited by 372
Arslanian, S., Bacha, F., Grey, M., Marcus, M. D., White, N. H., & Zeitler, P. (2018) · Diabetes Care · doi:10.2337/dci18-0052 · Cited by 349
Self-citationA brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS)
Siddiqui, S., Mateen, S., Ahmad, R., & Moin, S. (2022) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-022-02625-7 · Cited by 347
Maas, A. H. E. M., Rosano, G., Cifkova, R., Chieffo, A., van Dijken, D., Hamoda, H., Kunadian, V., Laan, E., Lambrinoudaki, I., Maclaran, K., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa1044 · Cited by 344
Current Guidelines for Diagnosing PCOS
Christ, J. P., & Cedars, M. I. (2023) · Diagnostics · doi:10.3390/diagnostics13061113 · Cited by 340
“Polymenorrhea (cycles occurring < 21 days apart) is relatively uncommon among patients with PCOS [52], however this feature has been included in some guidelines for the diagnosis of PCOS [23,53].”
BackgroundMartin, K. A., Anderson, R. R., Chang, R. J., Ehrmann, D. A., Lobo, R. A., Murad, M. H., Pugeat, M. M., & Rosenfield, R. L. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00241 · Cited by 339
“This recommendation is consistent with the Endocrine Society clinical guideline on the diagnosis and treatment of PCOS (40).”
BackgroundMethodInfluentialSelf-citationNaderpoor, N., Shorakae, S., de Courten, B., Misso, M. L., Moran, L. J., & Teede, H. J. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv025 · Cited by 334
Armanini, D., Boscaro, M., Bordin, L., & Sabbadin, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084110 · Cited by 324
Poly Cystic Ovarian Syndrome: An Updated Overview
El Hayek, S., Bitar, L., Hamdar, L. H., Mirza, F. G., & Daoud, G. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00124 · Cited by 323
Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome
Wang, J., Wu, D., Guo, H., & Li, M. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116940 · Cited by 322
Gurnani, M., Birken, C., & Hamilton, J. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2015.04.001 · Cited by 312
Barrea, L., Arnone, A., Annunziata, G., Muscogiuri, G., Laudisio, D., Salzano, C., Pugliese, G., Colao, A., & Savastano, S. (2019) · Nutrients · doi:10.3390/nu11102278 · Cited by 306
“Hyperandrogenism and/or biochemical hyperandrogenemia, oligomenorrhea due to secondary etiologies as per the Endocrine Society Clinical Practice Guidelines and previous publications including endocrine disorders (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing’s syndrome, hyperprolactinaemia, thyroi…”
BackgroundAdolescent polycystic ovary syndrome according to the international evidence-based guideline
Peña, A. S., Witchel, S. F., Hoeger, K. M., Oberfield, S. E., Vogiatzi, M. G., Misso, M., Garad, R., Dabadghao, P., & Teede, H. (2020) · BMC Medicine · doi:10.1186/s12916-020-01516-x · Cited by 301
Self-citationDeconstructing a Syndrome: Genomic Insights Into PCOS Causal Mechanisms and Classification
Dapas, M., & Dunaif, A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac001 · Cited by 300
Oocyte competence in women with polycystic ovary syndrome
Palomba, S., Daolio, J., & La Sala, G. B. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.11.008 · Cited by 294
He, F.-F., & Li, Y.-M. (2020) · Journal of Ovarian Research · doi:10.1186/s13048-020-00670-3 · Cited by 289
Complications and challenges associated with polycystic ovary syndrome: current perspectives
Palomba, S., Santagni, S., Falbo, A., & La Sala, G. B. (2015) · International Journal of Women's Health · doi:10.2147/ijwh.s70314 · Cited by 287
Dokras, A., Stener-Victorin, E., Yildiz, B. O., Li, R., Ottey, S., Shah, D., Epperson, N., & Teede, H. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.01.038 · Cited by 285
Xu, Y., & Qiao, J. (2022) · Journal of Healthcare Engineering · doi:10.1155/2022/9240569 · Cited by 283
“*e circulating C-reactive protein (CRP) observation also leads to the point that PCOS is concerned with low-grade chronic inflammation [81, 91].”
BackgroundNovel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus
Napolitano, A., Miller, S., Nicholls, A. W., Baker, D., Van Horn, S., Thomas, E., Rajpal, D., Spivak, A., Brown, J. R., & Nunez, D. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100778 · Cited by 282
“In addition, metformin improves the lipid profile [4], restores ovarian function in polycystic ovary syndrome [5], reduces fatty infiltration of the liver [6], and lowers microvascular and macrovascular complications associated with T2DM.”
BackgroundEffects of a Ketogenic Diet in Overweight Women with Polycystic Ovary Syndrome
Paoli, A., Mancin, L., Giacona, M. C., Bianco, A., & Caprio, M. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02277-0 · Cited by 281
“Guidelines [12] propose hormonal contraceptives as first-line management for menstrual abnormalities and hirsutism/acne in PCOS whilst metformin is suggested as treatment in women with PCOS and Type 2 diabetes or impaired glucose tolerance when lifestyle modification fail.”
Influential(2014) · PubMed Central · Cited by 280
Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update
Abraham Gnanadass, S., Divakar Prabhu, Y., & Valsala Gopalakrishnan, A. (2021) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-020-05951-2 · Cited by 272
“Besides, other diseases that may imitate these PCOS clinical traits should be omitted, which include hyperprolactinaemia, thyroid disease and adrenal hyperplasia (non-classical congenital) [15].”
BackgroundNaderpoor, N., Shorakae, S., de Courten, B., Misso, M. L., Moran, L. J., & Teede, H. J. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmv063 · Cited by 255
“Based on current guidelines, metformin is indicated in PCOS in some scenarios to improve fertility (Teede et al., 2011; Legro et al., 2013), for management of menstrual irregularity if women are unable to take OCPs, and in co-existent prediabetes or DM2, where lifestyle modification fails (Legro et…”
BackgroundInfluentialPsychiatric disorders in women with polycystic ovary syndrome: a systematic review and meta-analysis
Brutocao, C., Zaiem, F., Alsawas, M., Morrow, A. S., Murad, M. H., & Javed, A. (2018) · Endocrine · doi:10.1007/s12020-018-1692-3 · Cited by 251
Self-citationJoy, E., De Souza, M. J., Nattiv, A., Misra, M., Williams, N. I., Mallinson, R. J., Gibbs, J. C., Olmsted, M., Goolsby, M., Matheson, G., et al. (2014) · Current Sports Medicine Reports · doi:10.1249/jsr.0000000000000077 · Cited by 251
Overexpression of a DENND1A isoform produces a polycystic ovary syndrome theca phenotype
McAllister, J. M., Modi, B., Miller, B. A., Biegler, J., Bruggeman, R., Legro, R. S., & Strauss, J. F. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400574111 · Cited by 250
“Midday urine samples were obtained from five normal women and six women with PCOS, using the same clinical criteria described above for normal and PCOS theca cells, according to NIH consensus guidelines (10, 49).”
MethodSelf-citationMetabolic risk in PCOS: Phenotype and adiposity impact
Moran, L. J., Norman, R. J., & Teede, H. J. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.12.003 · Cited by 245
Legro, R. S., Dodson, W. C., Kris-Etherton, P. M., Kunselman, A. R., Stetter, C. M., Williams, N. I., Gnatuk, C. L., Estes, S. J., Fleming, J., Allison, K. C., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2778 · Cited by 242
Self-citationHypothalamic-Pituitary-Ovarian Axis Disorders Impacting Female Fertility
Mikhael, S., Punjala-Patel, A., & Gavrilova-Jordan, L. (2019) · Biomedicines · doi:10.3390/biomedicines7010005 · Cited by 232
“Several mechanisms describing pathogenesis of PCOS includes loss of GnRH pulsatility with increased LH secretion by the pituitary gland, hyperinsulinemia, ovarian insulin resistance, theca cell dysfunction and hyperandrogenism [12].”
BackgroundResistance to the Insulin and Elevated Level of Androgen: A Major Cause of Polycystic Ovary Syndrome
Ding, H., Zhang, J., Zhang, F., Zhang, S., Chen, X., Liang, W., & Xie, Q. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.741764 · Cited by 228
ISPAD Clinical Practice Consensus Guidelines 2018: Type 2 diabetes mellitus in youth
Zeitler, P., Arslanian, S., Fu, J., Pinhas-Hamiel, O., Reinehr, T., Tandon, N., Urakami, T., Wong, J., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12719 · Cited by 221
“• Metformin may normalize ovulatory abnormalities in girls with polycystic ovary syndrome (PCOS) (ovarian hyperandrogenism) and increase pregnancy risk.(92) • Metformin is approved for use during pregnancy.”
BackgroundSelf-citationPolycystic ovarian syndrome-current pharmacotherapy and clinical implications
Rashid, R., Mir, S. A., Kareem, O., Ali, T., Ara, R., Malik, A., Amin, F., & Bader, G. N. (2022) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2021.11.009 · Cited by 156
Functional genomics of PCOS: from GWAS to molecular mechanisms
McAllister, J. M., Legro, R. S., Modi, B. P., & Strauss, J. F. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.12.004 · Cited by 219
Self-citationDokras, A., Saini, S., Gibson-Helm, M., Schulkin, J., Cooney, L., & Teede, H. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.04.011 · Cited by 218
Greeley, S. A. W., Polak, M., Njølstad, P. R., Barbetti, F., Williams, R., Castano, L., Raile, K., Chi, D. V., Habeb, A., Hattersley, A. T., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13426 · Cited by 211
“For females, the hirsutism resulting from ovarian hyperandrogenism should be managed using similar strategies as for polycystic ovarian syndrome.(239)”
MethodSaadia, Z. (2020) · Medical Archives · doi:10.5455/medarh.2020.74.289-293 · Cited by 206
“PCOS is associated with long -term metabolic abnormalities and cardiovascular risks like insulin resistance, dyslipidemia, endothelial dysfunction, and elevated serum luteinizing hormone (LH) levels (2, 4, 5).”
BackgroundInfluentialTowards a multidisciplinary approach to understand and manage obesity and related diseases
Bischoff, S. C., Boirie, Y., Cederholm, T., Chourdakis, M., Cuerda, C., Delzenne, N. M., Deutz, N. E., Fouque, D., Genton, L., Gil, C., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.11.007 · Cited by 206
“Female patients may present with the polycystic ovary syndrome, including hyperandrogenism, oligo-amenorrhea and altered ovarian structure [16].”
BackgroundLiu, J., Wu, Q., Hao, Y., Jiao, M., Wang, X., Jiang, S., & Han, L. (2021) · Human Reproduction · doi:10.1093/humrep/deaa371 · Cited by 203
“However, it is difficult to diagnose PCOS during adolescence (Legro et al. , 2013), as the manifestations overlap with the physiological changes of puberty (Witchel et al. , 2019).”
Brown adipose tissue transplantation ameliorates polycystic ovary syndrome
Yuan, X., Hu, T., Zhao, H., Huang, Y., Ye, R., Lin, J., Zhang, C., Zhang, H., Wei, G., Zhou, H., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1523236113 · Cited by 202
Vitamin D and female fertility
Lerchbaum, E., & Rabe, T. (2014) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000065 · Cited by 143
“Lifestyle intervention is the first-line treatment for overweight and obese women with PCOS [18].”
BackgroundThe management of patients with polycystic ovary syndrome
Jayasena, C. N., & Franks, S. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.102 · Cited by 196
The Diagnosis of Polycystic Ovary Syndrome in Adolescents
Rosenfield, R. L. (2015) · Pediatrics · doi:10.1542/peds.2015-1430 · Cited by 195
Dennett, C. C., & Simon, J. (2015) · Diabetes Spectrum · doi:10.2337/diaspect.28.2.116 · Cited by 194
“In premenopausal patients not currently trying to become pregnant, the Endocrine Society recommends hormonal contraceptives as the first-line therapy to manage menstrual abnormalities and reduce hirsutism and acne (2,35).”
BackgroundEuropean Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity
Pasquali, R., Casanueva, F., Haluzik, M., van Hulsteijn, L., Ledoux, S., Monteiro, M. P., Salvador, J., Santini, F., Toplak, H., & Dekkers, O. M. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0893 · Cited by 188
Self-citationThe prevalence of polycystic ovary syndrome in adolescents: A systematic review and meta-analysis
Saei Ghare Naz, M., Ramezani Tehrani, F., Alavi Majd, H., Ahmadi, F., Ozgoli, G., Rashidi Fakari, F., & Ghasemi, V. (2019) · International Journal of Reproductive BioMedicine (IJRM) · doi:10.18502/ijrm.v17i8.4818 · Cited by 151
“In a study on 16- to 29-year-old Australian youth, the prevalence rate based on the NIH criteria was 12% (41).”
BackgroundPolycystic ovary syndrome and infertility: an update
Zehravi, M., Maqbool, M., & Ara, I. (2021) · International Journal of Adolescent Medicine and Health · doi:10.1515/ijamh-2021-0073 · Cited by 191
Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review
Harris, H. R., & Terry, K. L. (2016) · Fertility Research and Practice · doi:10.1186/s40738-016-0029-2 · Cited by 156
“Pharmacological agents are the first- and second-line treatments for many PCOS symptoms including: oral contraceptive use for oligomenorrhea, hirsutism, and acne; metformin for anovulatory infertility, oligomenorrhea, and type II diabetes prevention and treatment; and ovulation induction drugs (clomiphene and letrozol…”
BackgroundDiagnosis of Polycystic Ovary Syndrome
Chang, S., & Dunaif, A. E. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.10.002 · Cited by 190
Type 2 diabetes in the child and adolescent: T2D in the child and adolescent
Zeitler, P., Fu, J., Tandon, N., Nadeau, K., Urakami, T., Barrett, T., & Maahs, D. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12179 · Cited by 185
“• PCOS is diagnosed based on the presence of oligoor amenorrhea with biochemical or clinical evidence of hyperandrogenism, with or without evidence for polycystic ovaries (121).”
Lifestyle Modification Programs in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis
Domecq, J. P., Prutsky, G., Mullan, R. J., Hazem, A., Sundaresh, V., Elamin, M. B., Phung, O. J., Wang, A., Hoeger, K., Pasquali, R., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2385 · Cited by 184
“The accompanying clinical practice guidelines from The Endocrine Society will provide practical recommendations for the treatment of PCOS (47).”
MethodSelf-citationAnti-Müllerian Hormone in PCOS: A Review Informing International Guidelines
Teede, H., Misso, M., Tassone, E. C., Dewailly, D., Ng, E. H., Azziz, R., Norman, R. J., Andersen, M., Franks, S., Hoeger, K., et al. (2019) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.04.006 · Cited by 182
Self-citationPolycystic ovary syndrome throughout a woman’s life
Group of interest in Reproductive Endocrinology (GIER) of the Spanish Fertility Society (SEF), Bellver, J., Rodríguez-Tabernero, L., Robles, A., Muñoz, E., Martínez, F., Landeras, J., García-Velasco, J., Fontes, J., Álvarez, M., et al. (2018) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-017-1047-7 · Cited by 180
“Clomiphene citrate (CC) is considered the first-line treatment for ovulation induction in women with PCOS [43].”
BackgroundMethodDe Souza, M. J., Nattiv, A., Joy, E., Misra, M., Williams, N. I., Mallinson, R. J., Gibbs, J. C., Olmsted, M., Goolsby, M., & Matheson, G. (2014) · Clinical Journal of Sport Medicine · doi:10.1097/jsm.0000000000000085 · Cited by 180
“A pelvic ultrasound may be obtained in those with clinical or biochemical hyperandrogenism to confirm polycystic ovaries or to rule out virilizing ovarian tumors.(77,79) The primary care physician should refer to or consult with an endocrinologist for endocrine disorders they are not experienced in diagnosing or treat…”
BackgroundAndrogen excess: Investigations and management
Lizneva, D., Gavrilova-Jordan, L. P., Walker, W., & Azziz, R. (2016) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.05.003 · Cited by 178
The Rotterdam criteria for polycystic ovary syndrome: evidence-based criteria?
Wang, R., & Mol, B. W. J. (2017) · Human Reproduction · doi:10.1093/humrep/dew287 · Cited by 138
The Impact of Obesity on the Incidence of Type 2 Diabetes Among Women With Polycystic Ovary Syndrome
Kakoly, N. S., Earnest, A., Teede, H. J., Moran, L. J., & Joham, A. E. (2019) · Diabetes Care · doi:10.2337/dc18-1738 · Cited by 174
ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes in adolescence
Cameron, F. J., Garvey, K., Hood, K. K., Acerini, C. L., & Codner, E. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12702 · Cited by 155
Menstrual Cycle Effects on Sleep
Baker, F. C., & Lee, K. A. (2018) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2018.04.002 · Cited by 176
Newman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa674 · Cited by 172
Self-citationTreatment of adolescent obesity
Steinbeck, K. S., Lister, N. B., Gow, M. L., & Baur, L. A. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0002-8 · Cited by 171
ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents
Shah, A. S., Zeitler, P. S., Wong, J., Pena, A. S., Wicklow, B., Arslanian, S., Chang, N., Fu, J., Dabadghao, P., Pinhas‐Hamiel, O., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13409 · Cited by 170
Self-citationLegro, R. S., Dodson, W. C., Kunselman, A. R., Stetter, C. M., Kris-Etherton, P. M., Williams, N. I., Gnatuk, C. L., Estes, S. J., Allison, K. C., Sarwer, D. B., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1659 · Cited by 155
“3) [12] 1.”
Self-citationCarmina, E., Azziz, R., Bergfeld, W., Escobar-Morreale, H. F., Futterweit, W., Huddleston, H., Lobo, R., & Olsen, E. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02548 · Cited by 140
A review: Brief insight into Polycystic Ovarian syndrome
Bulsara, J., Patel, P., Soni, A., & Acharya, S. (2021) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2021.100085 · Cited by 167
Comorbidities and complications of polycystic ovary syndrome: An overview of systematic reviews
Gilbert, E. W., Tay, C. T., Hiam, D. S., Teede, H. J., & Moran, L. J. (2018) · Clinical Endocrinology · doi:10.1111/cen.13828 · Cited by 166
Metadata
- Authors
- Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K.
- Affiliations
- Pennsylvania State University (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-12
- Volume
- 98
- Issue
- 12
- Pages
- 4565-4592
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC5399492
- OpenAlex
- W2120973019
- Cited by
- 1,919
- References
- 356
- Citations by year
- 2026: 104 · 2025: 135 · 2024: 149 · 2023: 181 · 2022: 207 · 2021: 197 · 2020: 149 · 2019: 160 · 2018: 145 · 2017: 129 · 2016: 131 · 2015: 124 · 2014: 95 · 2013: 6
- FWCI
- 143.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institute of Diabetes and Digestive and Kidney Diseases (P60DK020595, P30DK020595)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD065029)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- polycystic ovary syndrome, PCOS diagnosis, Rotterdam criteria, hyperandrogenism, ovulatory dysfunction, PCOS treatment, hormonal contraception, clomiphene citrate, metformin, insulin resistance, menstrual irregularity, hirsutism, acne, infertility, adolescents, menopausal women, weight loss, lifestyle intervention, thiazolidinediones, statins, cardiovascular risk
- MeSH terms
- Adolescent, Adult, Age Factors, Female, Humans, Middle Aged, Polycystic Ovary Syndrome, Societies, Scientific, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.